PubRank

A Longhi

Author PubWeight™ 39.55‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000 2.06
2 Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000 1.77
3 Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br 2002 1.58
4 Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003 1.50
5 Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma. J Clin Oncol 2003 1.46
6 Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli. J Clin Oncol 2000 1.45
7 Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003 1.42
8 Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001 1.34
9 Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 2001 1.31
10 Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 2001 1.25
11 High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 2002 1.21
12 Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004 1.08
13 Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study. Acta Oncol 1998 1.01
14 Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute. Eur J Cancer 2002 0.97
15 Ewing's sarcoma family tumours. Differences in clinicopathological characteristics at presentation between localised and metastatic tumours. J Bone Joint Surg Br 2007 0.96
16 Prognostic significance of serum LDH in Ewing's sarcoma of bone. Oncol Rep 1999 0.92
17 Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol 2000 0.92
18 Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori 2000 0.89
19 Delay in diagnosis of high-grade osteosarcoma of the extremities. Has it any effect on the stage of disease? Tumori 2000 0.89
20 Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,. Clin Orthop Relat Res 2001 0.89
21 A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol 2001 0.86
22 Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. J Chemother 2001 0.85
23 Local and systemic control in Ewing's sarcoma of the femur treated with chemotherapy, and locally by radiotherapy and/or surgery. J Bone Joint Surg Br 2003 0.85
24 Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases. Acta Orthop Scand 2001 0.85
25 Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. Oncol Rep 1998 0.84
26 Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity. J Chemother 1998 0.84
27 Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 2000 0.83
28 Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients. Chemioterapia 1987 0.82
29 Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience. Oncol Rep 2000 0.81
30 Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. Eur J Surg Oncol 2006 0.80
31 [Asphyxiant thoracic dystrophy (Jeune syndrome). Clinical and medico-legal aspects]. Minerva Ginecol 1969 0.79
32 Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma. J Chemother 2009 0.79
33 Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment. Ann Oncol 2007 0.79
34 Ovarian function suppression with the gonadotrophin-releasing hormone (GnRH) analogue goserelin in premenopausal advanced breast cancer. Tumori 1994 0.78
35 High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients. Oncology 1991 0.78
36 [Notes on lipid metabolism in psoriasis]. Arch Ital Dermatol Venereol Sessuol 1966 0.77
37 Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma. Acta Oncol 1998 0.76
38 Fumonisin levels in commercial corn products in Buenos Aires, Argentina. Food Addit Contam 2000 0.76
39 A comment on "Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders". Eur J Cancer 2003 0.75
40 Measurement of ep-->e' ppi+ pi- and baryon resonance analysis. Phys Rev Lett 2003 0.75
41 [Clinical controlled trial on the use of a new local anesthetic Bledocaine, in urology]. Minerva Urol 1975 0.75
42 [Indications and results of the use of external fixation devices in traumatology of the hand]. Chir Organi Mov 1988 0.75
43 Q2 Dependence of quadrupole strength in the gamma*p --> Delta(+)(1232) --> p pi(0) transition. Phys Rev Lett 2002 0.75
44 [Accentuated dorso-lumbar scoliosis as a cause of failure of subarachnoid anesthesia]. Minerva Anestesiol 1986 0.75
45 [Controlled clinical study with pentazocine suppositories in postoperative analgesia]. Minerva Anestesiol 1977 0.75
46 [Contribution to the study of collagen nephropathy: clinical, functional and nephrobiotic observations]. G Clin Med 1964 0.75
47 [Personal experience with pancuronium in gynecologic surgery]. Ann Ostet Ginecol Med Perinat 1977 0.75
48 First measurement of the double spin asymmetry in (-->)e(-->)p-->e(prime)pi(+)n in the resonance region. Phys Rev Lett 2002 0.75
49 [Treatment with internal osteosynthesis of unstable metatarsal fractures]. Chir Organi Mov 1988 0.75
50 [Effects of Ketalar on the ocular tonus]. Minerva Anestesiol 1976 0.75
51 Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancer. Oncol Rep 1995 0.75
52 Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Oncol Rep 2001 0.75
53 Seven cases of primary heredoatrophy of the choroid. Panminerva Med 1975 0.75
54 Photofission of heavy nuclei at energies up to 4 GeV. Phys Rev Lett 2000 0.75
55 [Effects of the administration of Bayer 1420 (Epontol) on ocular tension]. Minerva Anestesiol 1967 0.75
56 [Blood loss during transvesical prostatectomy]. Minerva Anestesiol 1987 0.75
57 Eta photoproduction on the proton for photon energies from 0.75 to 1.95 GeV. Phys Rev Lett 2002 0.75
58 [Comparison of two different preanesthetic technics. Controlled clinical experiment]. Minerva Anestesiol 1986 0.75
59 [Analgesia by percutaneous electric stimulation in urologic endoscopy]. Minerva Anestesiol 1986 0.75
60 Long-term follow-up for patients with Ewing's sarcoma of bone treated with adjuvant and neoadjuvant chemotherapy. Oncol Rep 2011 0.75
61 First measurement of transferred polarization in the exclusive ep-->e'K+Lambda--> reaction. Phys Rev Lett 2003 0.75
62 [Primary reticulosarcoma of the mandible. Clinical and histopathological observations]. Minerva Stomatol 1987 0.75
63 Measurement of the proton spin structure function g1(x,Q2) for Q2 from 0.15 to 1.6 GeV2 with CLAS. Phys Rev Lett 2003 0.75
64 Observation of an exotic baryon with S=+1 in photoproduction from the proton. Phys Rev Lett 2004 0.75
65 [Complications of subarachnoid anesthesia. Our experience with 80 patients]. Minerva Anestesiol 1987 0.75
66 [Treatment of radiation-induced cutaneous lesions of the popliteal region with suprapatellar tubular flap]. Minerva Chir 1970 0.75
67 Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: a comparison of results obtained in single-institution and multicenter trials. Chir Organi Mov 2005 0.75
68 Medroxyprogesterone acetate plasma levels after a single oral administration of two drug formulations. Chemioterapia 1986 0.75
69 Activity of series of butyrophenone derivatives on the oxygen consumption by rat brain. Arzneimittelforschung 1970 0.75
70 [Fixed mydriasis in hemorrhagic shock treated with dopamine]. Minerva Anestesiol 1984 0.75
71 Chemotherapy of advanced malignant-melanoma (review). Oncol Rep 1994 0.75
72 The ep -->e'p eta reaction at and above the S11(1535) baryon resonance. Phys Rev Lett 2001 0.75